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Abstract 
Children with developmental disorders often have complex health needs and require 
frequent input from many different paediatric services. Genomic technologies have 
revolutionised how these disorders are diagnosed, and have the real potential to transform 
the management of previously intractable paediatric conditions. For paediatricians to fully 
harness these benefits for our patients, and to work productively with our clinical genetics 
colleagues within the multi-disciplinary team, we must be genomically literate and aware of 
the technical and ethical challenges. In this review article, we will summarise the current 
understanding of the genetic architecture of developmental disorders; discuss the different 
types of genetic tests currently available, their strengths and limitations in clinical practice; 
and discuss the challenges and future opportunities in paediatric genomic medicine.  
 
Introduction 
Developmental disorders are defined as diseases that arise in embryonic life or early fetal 
brain development and alter the developmental trajectory. In the UK, the majority of 
developmental disorders are believed to have a genetic aetiology. However, an important 
proportion are caused by exposure to environmental teratogens such as alcohol, sodium 
valproate; or in utero infection by pathogens such as Toxoplasma, cytomegalovirus or Zika 
virus. While individual developmental disorders are often extremely rare, collectively they 
are common: approximately 2-3% of children are born with major congenital anomalies 
and/or demonstrate severe neurodevelopmental disorders. These children often have 
complex health needs, and will frequently require paediatric input. Indeed, McCandless and 
others have found that a third of paediatric inpatient admissions are of children with a 
genetic underlying disorder, with up to half of acute inpatient healthcare costs attributable 
to their care. Until recently, many of these children did not receive a specific genetic 
diagnosis. However, the advent of “next-generation sequencing” (NGS) technologies has 
driven down the cost of genetic testing and made it available within routine clinical practice. 
Patient diagnosis and care is best delivered by a multi-disciplinary team, involving clinical 
geneticists and paediatricians together with other health professionals. While the role and 
expertise of the clinical geneticist is more crucial than ever, families correctly expect their 
paediatricians to be up to date with this fast-developing field. Furthermore, as diagnosis 
rates increase, we have an opportunity to pursue targeted treatments for individual 
developmental disorders. Such personalised medicine has the real potential to transform 
the management of previously intractable paediatric conditions. However, for paediatricians 
to fully harness these benefits for our patients, we must be genomically literate and aware 
of the technical and ethical challenges. In this review article, we will discuss the benefits to 
the child and their family of establishing a genetic diagnosis; summarise the current 
understanding of the genetic architecture of developmental disorders; discuss the different 
types of genetic tests currently clinically available, their strengths and limitations; and 
discuss the challenges and future opportunities in paediatric genomic medicine.  
 
1. Why establish a genetic diagnosis? 
There are advantages and disadvantages to pursuing a genetic diagnosis, and the balance 
between the two will be specific to each family. Different families may therefore make very 
different decision with regards to whether to pursue genetic diagnosis. Paediatricians are 
increasingly taking consent for some forms of genetic testing, such as karyotyping and 
microarray analyses, and we have a responsibility to ensure that this consent is fully 
informed and therefore valid. The advantages of establishing a specific genetic diagnosis 
include informing clinical management through condition specific medical and prognostic 
information; the emotional closure that may come with establishing a diagnosis; accuracy of 
advice regarding risk to other family members; and access to patient support groups.  
Indeed, there is evidence that although most developmental disorders do not have curative 
treatments, obtaining a genetic diagnosis alters clinical management in 70% of cases, by 
informing symptomatic management and clinical monitoring. Having a specific genetic 
diagnosis may allow a family to access reproductive counselling if they wish, including, in 
some cases, pre-implantation or pre-natal genetic diagnosis in future pregnancies. Families 
often report that access to support groups and a community of similarly affected individuals 
can be of significant practical help, and can allay the sense of isolation that many families 
experience when they have a child affected by a rare disorder. However, families must also 
be warned of the possibility of identifying variants of uncertain significance (VUS) and 
incidental findings (see Boxes 1, 2 and Table 2), and it is important to adequately explore 
with them how they would feel about receiving prognostic information regarding their 
child’s condition. For example, some families would not wish to know that their neonate has 
a significant risk of developing intellectual disability. For others, there may be a stigma 
associated with genetic diagnoses. These views must be respected although where a genetic 
diagnosis has the potential to substantially alter clinical management, this should be 
carefully explained to ensure that the preference is well-informed and in the child’s best 
interest. See Box1 for more practical details regarding taking consent for genetic testing. 
 
2. The genetic architecture of developmental disorders 
The genetic abnormalities that can result in developmental disorders range in scale from 
chromosomal disorders such as aneuploidies – having missing or extra chromosomes – 
through to the change of single base, a single nucleotide variant (SNV). There is a 
corresponding range of genetic tests available, each with a different resolution, and with 
clinical advantages and disadvantages (Table1). As the resolution of the genetic test 
increases, so does the volume of data which it generates. This raises analysis, data-
management and ethical challenges, including an increasing risk of identifying VUS and 
incidental findings. High-resolution tests (such as whole-genome sequencing) are also 
substantially more expensive. Therefore, it is important to choose the most appropriate 
genetic test for the likely genetic abnormality in a particular clinical presentation, and to 
counsel parents regarding which genetic anomalies may be confidently excluded by the test, 
and which cannot. 
 
2.1  Structural variants and uniparental disomy: 
2.1.1 Aneuploidies 
In aneuploidies there are an abnormal number of chromosomes in each cell. For example, in 
trisomies there are three copies of a chromosome, in monosomies only one. The 
commonest aneuploidy is Trisomy 21 (Down’s syndrome), with a prevalence in the UK of 
approximately 1 per 1000 births. Other aneuploidies include Patau’s syndrome (Trisomy 13) 
and Edward’s syndrome (Trisomy 18), Klinefelter’s syndrome (47,XXY), XYY syndrome 
(47,XYY) Triple X syndrome (47,XXX) and Turner’s syndrome (45,X). Most aneuploidies are 
caused by non-disjunction – the failure of correct separation of the homologous 
chromosomes or sister chromatids during cell division. Non-disjunction events in the early 
embryo can result in mosaic aneuploidies, where there is a mixture of cells in the embryo, 
some with the correct number of chromosomes, and others bearing an aneuploidy. 
Occasionally aneuploidies are caused by translocation events – where part of one 
chromosome becomes attached to another. This is important because an unaffected parent 
may carry a Robertsonian or a balanced translocation – where they have the correct amount 
of genetic information, but it is distributed in an unusual way. For example, translocation of 
the long arm of chromosome 21 to the long arm of chromosome 14 results in a balanced 
Robertsonian translocation. The individual carrying this unusual chromosome is unlikely to 
have any symptoms, however they have an increased risk of having a child with Down’s 
syndrome. Correct identification of such translocations is therefore important for accurate 
counselling of recurrence risk, and requires careful selection of the appropriate genetic test 
(Table1). Aneuploidies can be detected with many types of genetic testing. A quantitative 
PCR is the fastest, and can provide a rapid diagnosis in a few days, but cannot exclude 
mosaic aneuploidy. Quantitative PCR will give information regarding the dosage of 
chromosomes, but will not give any information regarding how the genetic material is 
structured. Karyotype analysis – where the physical structure of chromosomes is 
interrogated – is useful for identifying any underlying translocations, and is therefore 
particularly important in cases of recurrent aneuploidy (Table 1).  
  
2.1.2  Uniparental disomies 
When a child has a uniparental disomy, their cells contain the correct number of 
chromosomes, however both copies of a chromosome have been inherited from the same 
parent. This usually occurs as a consequence of rescue of lethal trisomies caused by non-
disjunction events. For most genes, this does not affect their expression. However, 
approximately 100 genes are subject to genomic imprinting, where their expression is 
strictly regulated in a parent-of-origin manner. For example, some genes are expressed only 
from the maternally-inherited allele, and others from the paternally-inherited allele. In 
uniparental disomy, the inheritance of two chromosomes from the same parent will alter 
the expression dosage of imprinted genes on that chromosome, which can perturb 
development. For example, trisomy of chromosome 15 is lethal, however the correction of 
such a trisomy in the early embryo resulting in paternal uniparental disomy of chromosome 
15 causes Angelman Syndrome, while maternal uniparental disomy of chromosome 15 
causes Prader Willi Syndrome. This can be detected using NGS approaches or by specifically 
looking for methylation marks which differ at imprinted regions based on which parent they 
were inherited from using methylation sensitive MLPA (multiplex ligation dependent PCR 
amplification). 
 
2.1.3 Copy number variants 
Copy number variants (CNVs) refer to deletions or duplications of parts of chromosomes, 
and are estimated to account for about 14% of developmental disorders. However, not all 
CNVs cause disease, and many CNVs show variable penetrance – not all individuals carrying 
the CNV will have the disease – and variable expressivity – there is variability in the severity 
of the associated phenotype. There are several factors that affect whether a CNV is likely to 
be pathogenic. In general, large and gene-rich CNVs are more likely to be pathogenic, and 
deletions are often more damaging than duplications. Currently, CNVs are tested for 
clinically by microarray, targeted FiSH, MLPA, and, if large, karyotype analysis (Table 1). 
Recent improvements in analysis techniques applied to exome and whole genome 
sequencing data are proving useful in the detection of CNVs, particularly if they are small, 
however these are not yet in routine clinical use. 
 
The trinucleotide repeat expansion disorders are caused by the increased copy-number of a 
trinucleotide repeat, and deserve particular mention due to the specific clinical tests 
required to diagnose them. They are an important cause of neurodevelopmental and 
neuromuscular disorders, and include Fragile X syndrome - caused by the expansion of a 
(CGG)n repeat, Friedrich’s Ataxia – (GAA)n, and Myotonic Dystrophy type 1 – (CTG)n. It is 
important to appreciate that these disorders are not yet easily identified by sequencing 
technologies including NGS, and instead a specific triplet primed PCR assay is used (Table 1). 
 
2.2 Monogenic disorders 
A rapidly expanding number of genes have been reported to be associated with 
developmental disorders. SNVs, small insertions or deletions, or CNVs that alter the function 
of these genes interfere with normal developmental processes. Historically, recurring 
phenotypic patterns were grouped into syndromes by clinical assessment, and if the 
causative gene had been identified, a genetic diagnosis could be sought by Sanger 
sequencing. However, some clinical presentations such as early infantile epileptic 
encephalopathy or intellectual disability can be caused by a very large number of genes, 
with few distinguishing clinical features. As the cost of NGS technologies has dropped, it is 
now cheaper to sequence an exome, the protein-encoding portion of the genome, than to 
sequence more than a few genes using Sanger sequencing. Analysis of the exome data is 
then often limited to a list of genes on a virtual gene panel known to be associated with a 
given clinical presentation (e.g. neuronal migration disorders). Consequently, NGS based 
approaches – encompassing exomes, exome-based gene-panels and whole-genome 
sequencing – are increasingly being used in clinical practice. Gene agnostic approaches such 
as exome or whole-genome sequencing have resulted in a widening of the phenotypic 
spectrum of many clinically defined genetic syndromes, and have demonstrated that 
multiple genetic diagnoses may be found in up to 5% of patients. However, these 
techniques dramatically increase the amount of data generated, making analysis 
substantially more complex, increasing the risk of false positives, false negatives and VUS 
(see Table 1 and Box 1).  
 
2.2.1 Challenges in interpreting genetic variants  
As we all carry 4-5 million genetic variants (sites where our genome differs from the 
reference sequence), it can be challenging to identify whether an observed genetic change 
is responsible for a phenotype, or whether it is part of normal inter-individual variation. 
Widespread adoption of the American College of Medical Genetics and Genomics (ACMG) 
guidelines on variant interpretation has fostered a systematic approach to variant 
classification by clinical scientists (Table 2). Candidate diagnostic findings are best discussed 
with a multidisciplinary team, including a clinical geneticist or clinician with clinical and 
genomic expertise in the disorders being assessed. Sequence variants which are predicted 
to severely disrupt a protein-coding sequence, for example by the introduction of a stop 
codon or a frame-shift are called loss-of-function (LoF) variants and are more likely to cause 
disease than variants which do not alter the amino acid sequence - synonymous variants. 
However, LoF variants in many genes do not appear to cause disease. Missense variants 
change the amino acid sequence, and predicting whether this alters the function of the 
protein can be difficult. There are many computational algorithms which aim to predict the 
consequence of missense variants, and these are utilised in clinical practice, however their 
results can be contradictory. The use of population genetic databases such as the Genome 
Aggregation Database (GnomAD) to prioritise variants has therefore become essential. 
Variants which are common among healthy adult members of the general population are 
highly unlikely to be responsible for a monoallelic rare, severe developmental disorder. 
Family based analysis – where both the child and their parents are sequenced in a trio – is 
also invaluable. If the parents are not affected by a severe developmental disorder, it is 
likely that the genetic cause will be either a new variant that has arisen in the child – a de 
novo variant in a dominant or haploinsufficient gene – or the inheritance of two copies of a 
damaging variant in a recessive gene but other possibilities such as X-linked inheritance and 
inherited variants in imprinted genes need to be borne in mind. A good knowledge of 
genetics is important in interpreting results from genetic tests and knowing whether 
possible causes may have been missed either by the choice of test or its analysis.  Despite 
these steps, VUS are a common outcome of genetic tests, and can cause significant anxiety 
for patients. Many variants classified as ‘likely pathogenic’ will have a 10% risk of not being 
disease-causing so further assessment is usually indicated especially if any clinical or 
reproductive decisions are likely to be based on the diagnosis (Table 2). Some individuals 
with pathogenic variants will be asymptomatic if the disorder shows incomplete penetrance 
or may have only very subtle signs if there is highly variable expressivity. Furthermore, it is 
unclear whether our duty of care extends to the regular re-analysis of VUS in the light of 
new information, shown in research studies to yield clinical benefit, and if so, how this is to 
be accommodated within health care services. 
 
2.2.2 Developmental disorders and de novo genetic variants  
Studies such as Deciphering Developmental Disorders (DDD) have demonstrated that the 
genomes of children with severe developmental disorders are enriched for damaging 
genetic variants that have occurred de novo, i.e. they have arisen for the first time in the 
child, and have not been inherited from either parent. DDD carried out exome sequencing 
on ~14,000 children with severe developmental disorders and their parents. This large 
sample size enabled an estimation of the prevalence of severe developmental disorders 
caused by damaging de novo variants as between 1 in 213 and 1 in 448, depending on 
parental age. The risks are lowest for younger parents and highest for older parents with the 
age of the father having a larger effect than that of the mother.  
 
2.2.3 Recessive developmental disorders 
The likelihood of a developmental disorder being recessive increases if there are affected 
siblings and if an individual has large stretches of autozygosity – segments of DNA that are 
identical (homozygous by descent) as a result of inheritance. A detailed family history, and 
careful enquiry as to whether there is any consanguinity in the family is important. The 
proportion of developmental disorders caused by recessive genetic variants is not known, 
however it was estimated in the DDD study to be approximately 4% among individuals of 
European ancestry, and 30% among individuals of Pakistani ancestry, in whom a higher 
burden of autozygosity was identified. However, 6% of individuals with autozygosity 
indicative of a first-cousin union or closer were found to have a plausible causative de novo 
variant, which underlines the importance of looking for damaging de novo variation even 
among individuals with a history of consanguinity.     
 
3. Diagnosing the undiagnosed 
Cohort studies typically find that whole exome or whole genome sequencing identifies a 
diagnosis for ~40% of children with severe developmental disorders. Greater severity of 
developmental delay, multi-system involvement and neuromuscular features tend to be 
associated with a higher rate of diagnosis. There are considerable international research 
efforts ongoing trying to identify what are the underlying causes for the remaining ~60% of 
children. A minority are likely to be caused by rare genetic variation in currently unknown 
developmental disorder genes. However, it is likely that we will need to look beyond 
monogenic patterns of inheritance if we are to uncover all the aetiologies of developmental 
disorders. Other possible causes include oligogenic and polygenic inheritance, non-coding 
variants and environmental factors. 
 
3.1  Identifying new developmental disorder genes 
Traditionally, new developmental disorder genes have been identified by gathering groups 
of similarly affected individuals and searching for a commonly affected gene – a phenotype 
driven approach. However, with the falling cost of NGS, it has been possible to identify new 
developmental disorders through a purely statistical genotype-driven approach. As 
individual developmental disorders are extremely rare, very large cohort sizes are necessary 
to have sufficient statistical power. However, this technique has been demonstrated to 
work when analysing disparate developmental disorders together. In simplistic terms, the 
number and type of genetic variants expected in each gene can be estimated, using large 
databases of the genetic variation observed in the normal, healthy population – such as 
GnomAD. In a cohort of individuals with developmental disorders, the genes responsible will 
have more damaging genetic variants (variants that result in a loss-of-function of the 
protein, and missense variants) than expected. This allows new genetic disorders to be 
identified in an unbiased manner. Given the rarity of severe developmental disorders, 
international sharing of data between large patient cohorts will be required in order to 
maximise the clinical benefits, improve our understanding of the genetic architecture of 
developmental disorders and achieve diagnoses for as many patients as possible. These 
considerable benefits must be balanced against our duty of confidentiality to patients and 
the risks of highly identifiable personal genomic information being made public (see Box1). 
 
3.2  Polygenic inheritance 
In polygenic inheritance many different genetic loci contribute to the expression of a trait. 
Examples include height, weight and BMI. The majority of the genetic variants involved are 
common, in the non-coding portion of the genome, and each makes a small impact on 
phenotypic expression, which is modified by environmental factors. Until recently, it was 
thought that this sort of genetic variation was unlikely to play a significant role in rare, 
severe developmental disorders, thought to be monogenic. However, a recent study by 
Niemi et al. has suggested that approximately 8% of the variance in risk for 
neurodevelopmental disorders can be attributed to common genetic variants. This is similar 
to that which has been reported for common disorders such as depression. In this study 
there was no difference in the contribution of common genetic variation between 
individuals in whom a monogenic cause had been identified and those in whom it hadn’t. 
This suggests that common genetic variation contributes to the overall risk for 
developmental disorders, and may also modify the expression of individual phenotypes. 
 
3.3 Oligogenic inheritance 
This describes a situation where the inheritance of variants in several genes is required to 
produce a phenotype. For example, fascioscapulohumeral dystrophy type 2 requires both a 
rare SNV in the gene SMCHD1, and a permissive DUX4 allele for expression of the disease 
phenotype. Digenic models have also been identified in Bardet-Biedl syndrome, retinitis 
pigmentosa and midline craniosynostosis. Furthermore, in hereditary neuropathies, an 
increased burden of rare non-synonymous variation in neuropathy associated genes may 
modify the expression of other highly penetrant alleles, suggesting that mutational load 
may contribute to disease. This pattern of genetic aetiology can be challenging to identify 
but may underlie many of the currently undiagnosed cases. 
 
3.4 Non-coding genetic variants 
Non-coding DNA refers to all genetic sequence which does not encode for proteins. This is 
the vast majority of our DNA. Previously termed “junk” DNA, much of the non-coding 
genome is now thought to regulate expression of the coding sequence, controlling where, 
when and how genes are turned on and off. Establishing the functional significance of non-
coding genetic variation is challenging for two major reasons. Firstly, our knowledge of how 
regulatory elements work remains largely rudimentary. It is therefore often difficult to 
predict which variants might disrupt gene expression, unlike in coding regions, when we are 
able to predict the consequence of a variant on the encoded amino acids. Secondly, it is not 
straightforward to identify the target gene(s) of non-coding regions, so it is difficult to assign 
the variant to the gene that it affects. However, the disruption of regulatory regions by 
CNVs resulting in perturbed gene expression and developmental disorders have been 
reported. Furthermore, SNVs in the Shh regulatory region on chromosome 7q36 have also 
been shown to result in abnormalities of limb bud development, including pre-axial 
polydactyly, tri-phalangeal thumb and syndactyly. However, a more general understanding 
of the contribution of non-coding variation to rare developmental disorders has been 
elusive. A recent study by Short et al. attempted to look at the contribution of de novo 
genetic variation in non-coding regions to developmental disorders. They observed an 
enrichment of de novo mutations in highly conserved fetal brain-active enhancers in 
neurodevelopmental disorders. However, they estimate that only 1-3% of undiagnosed 
developmental disorder patients are likely to carry a pathogenic de novo non-coding variant 
in a fetal brain-active enhancer.  
 
4. Future opportunities and challenges 
NGS technologies and their application to large cohorts of children with disparate 
developmental disorders have revolutionised our ability to provide families with a genetic 
diagnosis. As discussed above, there is still progress to be made in identifying the aetiologies 
responsible for those children currently without a genetic diagnosis. Another significant 
challenge is in variant interpretation. As large-scale high-resolution genetic tests are 
increasingly used in clinical practice, so the number of VUS is accelerating. VUS often cause 
significant anxiety for patients and their families, and it is unclear whether our clinical duty 
of care extends to regular re-analysis of previously reported VUS in the light of new data, 
and if so, how this can be accommodated within health care services. New technologies that 
allow the empirical high-throughput testing of the functional consequences of large 
numbers of variants in cellular systems may substantially improve our ability to interpret 
variants, with significant clinical benefits. Finally, genomic technologies are opening up a 
new era of possibilities in the treatment of rare disease. There are inspiring examples where 
new genetic diagnoses have suggested a mechanism and targeted treatment, resulting in 
startling clinical improvements for patients. Using genomic technologies to stratify clinical 
trial patient cohorts may reduce heterogeneity in treatment response, and so allow the 
development of effective targeted treatments for specific aetiologies. Although substantial 
technical, safety and ethical issues remain, in the longer term, gene editing and gene 
therapy approaches hold the promise of corrective therapy for certain conditions.  
 
Conclusion 
The application of genomic technologies has revolutionised how we approach the diagnosis 
of children with developmental disorders. The aspiration to provide a specific genetic 
diagnosis for each child with a monogenic condition, although not yet achieved, now seems 
realistic. A new era of potential therapeutic developments is just beginning, and there is 
good cause for the optimism. Children with developmental disorders make up a significant 
part of our paediatric population, as paediatricians we must work together with our clinical 
genetics colleagues to ensure that the full benefits of genomic technologies are realised for 




BOX 1 Ethical issues of genomic testing 
Genetic testing in children has always raised ethical, social and legal issues, such as 
informed consent in minors, best-interests decision making, reproductive autonomy, 
incidental findings, predictive testing and the implications of genetic data for relatives. 
Many of these issues are amplified by the scale and depth of genomic data, but there are 
also novel considerations raised by genomic scale analyses: 
Balancing confidentiality and the benefits of data sharing 
An individual’s genome sequence is unique to them, and is therefore highly identifying. 
Patients are often concerned about the possibility of genetic discrimination. Anonymisation 
is not a sufficient safeguard, as several studies have shown that re-identification is possible 
using just a tiny proportion of an individual’s genome. This can have significant unintended 
consequences for other family members, in addition to the child tested, some of which may 
not be foreseeable. However, given our incomplete knowledge of the genome, in order to 
interpret genomic data and gain maximum clinical benefit, we need to compare an 
individual’s data against that of many others, necessitating the sharing of this data. A 
proportionate approach to data sharing is developing within the field. This allows for these 
clinical benefits to be realised through the carefully managed secure sharing of anonymised 
individual genomic data and detailed phenotypic descriptions with other clinicians and 
authorised researchers, while much more limited and less identifiable data – likely 
diagnostic variants with a limited phenotypic description – is shared openly through 
platforms such as the DECIPHER database and Matchmaker Exchange (Table 3), facilitating 
the identification of new genetic conditions, and realising considerable patient benefit. 
Incidental findings 
Incidental findings are commonly encountered in many diagnostic tests, and should be 
routinely discussed when obtaining consent. However, genetic data has the potential to give 
predictive information – for example, regarding a patient’s future risk of developing breast 
cancer or dementia – and the possible consequences of this need to be considered, 
particularly in children who lack capacity to consent. The ACMG has identified 59 medically 
actionable genes in which they recommend feeding back damaging genetic variants to the 
adult patient as secondary findings when sequencing has been undertaken for other 
reasons. However, there is no prospective data on the benefits and risks of such 
opportunistic screening. As current clinical practice is to not undertake predictive testing in 
a child for any later-onset condition until they have the capacity to consent, only 
information regarding childhood-onset conditions are returned. However, it is unclear 
whether our clinical duty of care extends to reassessing this when the child reaches the age 
of majority, and if so, how to deliver this within the health care system. 
 
 
BOX2 Taking consent for genetic tests 
Often the child does not have capacity to consent for themselves, so consent is given by the 
parents in the best interest of the child. However, where possible the child should be 
involved in this process. The broad domains that should be covered to ensure that consent 
is informed and valid are below. Consent should be taken by the most appropriate clinician, 
and for many genetic tests this will remain a clinical geneticist. However, consent for 
microarray testing is increasingly being taken by paediatricians. Therefore, we will discuss 
the principles of consent in the context of the following clinical vignette: a baby is born with 
a cleft palate and tetralogy of Fallot.  
1. What the test checks for and what it cannot exclude: 
“A microarray checks for big pieces of missing or duplicated DNA in our “instruction 
manual”. We know that sometimes this can cause heart and palate problems. However, if 
the test is normal, there might still be a genetic cause. This is because the test does not 
check for certain genetic changes – there may still be small sentences missing, or spelling 
mistakes in the genetic information. We may therefore suggest doing further tests in the 
future. “ 
2. Variants of uncertain significance: 
“Our understanding of the human genetic code is not complete, and therefore sometimes 
we find things where we are unsure what they mean. For some genetic changes, we may 
not be able to give you a clear answer as to whether it’s the cause of your son’s heart defect 
and cleft palate. We call these variants of uncertain significance. We may need to take blood 
tests from yourselves, the parents, to try to interpret the results.”  
3. Incidental findings 
“We are doing this test to see if we can find a reason why your baby has a cleft palate and a 
problem with his heart. However, by doing this test, we sometimes find additional 
information that we weren’t looking for – for example, we may discover that your baby may 
have an increased risk of learning difficulties.” 
 
Table 1 – Common Genetic tests, their resolution and clinical application. 
 


















N/A Aneuploidy  0-1 Fast – result 
usually within 3 
days 
Only available for specific 
chromosomes (13, 18, 21, 
X, Y) 








0-1 Looks at 
structure – 
translocations 




Small CNVs will not be 
seen.  
A baby with 
Trisomy 21 is born 
to a family history 
of Trisomy 21, does 









5-100Mb 2 million CNVs 10-100s Smaller CNVs 
identified. 
Genetic dosage but not 
structure is interrogated. 
If a deletion/duplication 
identified at the end of a 
chromosome, advisable to 
perform a karyotype to 
look for translocations. 
 
A baby is born with 
a cleft palate and 
tetralogy of Fallot. 











0-1 Fast – result 
usually within 1 
week 
A specific test must be 
developed and validated 
for each region, therefore 
it is only available for 
some conditions. 
A baby is born with 
a cleft palate and 
tetralogy of Fallot. 
Does this baby have 
22q11.2 deletion 
syndrome? 



















A specific test must be 
developed and validated 
for each region, therefore 
it is only available for 
certain genes. 
A sweat test 
suggests a baby has 
CF, but genotyping 
of common variants 
is normal. MLPA 
for exonic deletions 






















A specific test must be 
developed and validated 
for each region. 





Triplet primed PCR 
is requested for 
Fragile X 
syndrome. 
















1. Must have a strong 
clinical suspicion of 
what gene to test. 
2. Needs to be paired 
with MLPA to detect 
exonic deletions. 
A sweat test 
suggests a baby has 
CF, but genotyping 
of common variants 
is normal. MLPA 
for exonic deletions 














1. Only the genes on the 
panel will be analysed. 
As more genes are 
associated with 













panels will need to be 
regularly updated. 









gene panel is sent. 





~20,000 Unbiased, all 







1. Only ~30% of genes 
have a known disease 
association  
2. Predicting the 
consequence of 
variants is not 
straightforward and 
requires both clinical 
and molecular 
assessment.  
3. VUS are common 
4. Trio-based approaches 
have the potential to 
reveal non-paternity. 
5. Trinucleotide repeat 
expansions are not 
currently detected. 




Gene panel testing 
is negative, so DNA 
from the child and 
both parents is sent 





1bp ~3 billion Most 
variants 
4-5 million Unbiased, all 





1. Only ~30% of genes 
have a known disease 
association  
2. Predicting the 
consequence of 
variants is not 




Gene panel testing 




is easier than 
with exomes. 
straightforward and 
requires both clinical 
and molecular 
assessment.  
3. VUS are common 
4. Trio-based approaches 
have the potential to 
reveal non-paternity. 
5. Trinucleotide repeat 
expansions are not 
currently detected. 
6. The majority of the 
noncoding genome is 
not currently 
interpretable. 
from the child and 
both parents is sent 
for trio whole 
genome sequencing 
 





Evidence needed for 
variant classification 
(simplified) 
How can this variant be used in the 
clinic? 








- A well-established 
disease-causing variant 
with consensus on 
pathogenicity 
- Co-segregation with the 
disease observed in 
several families 
- Functional studies have 
detailed the pathogenic 
effect 
- Variant not seen or very 
rarely seen in healthy 
populations. 
Together with other laboratory data, 
this variant can sometimes be used to 
predict the phenotype, and therefore 




- Screening all relatives who may 
have inherited the variant 
- Pre-natal diagnosis 
 
However, beware incomplete 
penetrance and variable expressivity. 
 





0.9 < p < 0.99 
 
Lacks some evidence for a 
class 5 variant. Many 
disease-causing but novel 
variants, particularly in less 
studied genes will be class 
4. 
Could be cautiously used for clinical 
management, but ongoing review of 
variant status is required. 
- Could additional investigations (e.g. 
biochemical studies) provide new 
evidence? 
- Should not be used for predictive 
testing or prenatal diagnosis without 
discussion with a Clinical Genetics 
unit. 






0.1 < p < 0.9 
Variant has conflicting 
evidence – some disease-
causing characteristics, 
other data suggests it may 
be benign (e.g. seen at high 
frequency in a healthy 
population). 
OR 
Insufficient evidence to 
categorise the variant. 
Should not be used to guide clinical 
decision making. 
- Could co-segregation (testing 
relatives) or functional studies 
facilitate reclassification to class 2 or 
4?  
If undertaken, be clear with relatives 
that this is not screening for disease. 
- Be aware that variant classification 
may change over time, and should be 
reviewed. 





Variant found more 
commonly in the healthy 
population than expected 
for the frequency of the 
disease. 
Normally not reported, as not clinically 
actionable 





- Variant does not 
segregate with disease in 
families with >2 affected 
individuals. 
- Functional studies 
demonstrate no 
significant effect of 
variant. 
Normally not reported, as not clinically 
actionable 
 
Table 3: Online resources and their clinical utility 
Online resource Description of 
resource 




Genetics Home Reference 
https://ghr.nlm.nih.gov/resources 
Describes what is 
known about clinical 
syndromes and 
human genes 
- Is the causative gene 
known for this 
condition? 
- What phenotypes are 
associated with this 
condition? 
- Are any clinical 
disorders associated 













- Are there other patients 
with the same or similar 
variants in this gene? 
What are their 
phenotypes?  
- Are there patients who 
have CNVs that remove 
the gene that my 
variant is in? 
- How common are 
damaging variants in 
this gene in healthy 











in an effort to 
‘solve’ unresolved 
cases. 
- Are there other 
patients with similar 
variants and similar 
phenotypes? Could this 
represent a new 
condition? 
Genetic Alliance UK 
https://www.geneticalliance.org.uk  
A coalition of 
organisations that 
support individuals 
and families with 
rare genetic 
conditions. 
- Is there a patient 
support group or 
charity that I could 
direct my patient and 
their family to, if they 
are interested? 
- Educational resources 
on genetics and genetic 
disorders. 
 
Take home messages: 
• NGS technologies have the power to improve diagnosis and treatment of rare 
paediatric disease. 
• Interpreting genomic data is complex. 
• Making a diagnosis of a severe, life-long genetic disease in a young person is a major 
step and due diligence is required to ensure that the diagnosis is clinically and 
molecularly robust. 
• Consider referral to a Clinical Geneticist or colleague with expert knowledge of the 
specific genetic diagnosis under consideration. Clinical experience of the 
presentation and progression of disease remains crucial to recognise when an 
erroneous diagnosis has been made or when the genetic test explains only part of 
the clinical presentation and there is a second important diagnosis to make.  




We thank Drs S Sabanathan and T Rossor for helpful comments on the text. 
 
Reading List: 
1 Wright, C. F., FitzPatrick, D. R. & Firth, H. V. Paediatric genomics: diagnosing rare 
disease in children. Nat Rev Genet 19, 325, doi:10.1038/nrg.2018.12 (2018). 
2 McCandless, S. E., Brunger, J. W. & Cassidy, S. B. The burden of genetic disease on 
inpatient care in a children's hospital. Am J Hum Genet 74, 121-127, 
doi:10.1086/381053 (2004). 
3 Deciphering Developmental Disorders, S. Prevalence and architecture of de novo 
mutations in developmental disorders. Nature 542, 433-438, 
doi:10.1038/nature21062 (2017). 
4 Martin, H. C. et al. Quantifying the contribution of recessive coding variation to 
developmental disorders. Science 362, 1161-1164, doi:10.1126/science.aar6731 
(2018). 
5 Niemi, M. E. K. et al. Common genetic variants contribute to risk of rare severe 
neurodevelopmental disorders. Nature 562, 268-271, doi:10.1038/s41586-018-0566-
4 (2018). 
6 Wright, C. F., Hurles, M. E. & Firth, H. V. Principle of proportionality in genomic data 
sharing. Nat Rev Genet 17, 1-2, doi:10.1038/nrg.2015.5 (2016). 
7 Firth, H. V. et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in 
Humans Using Ensembl Resources. Am J Hum Genet 84, 524-533, 
doi:10.1016/j.ajhg.2009.03.010 (2009). 
8 de Ligt, J. et al. Diagnostic exome sequencing in persons with severe intellectual 
disability. N Engl J Med 367, 1921-1929, doi:10.1056/NEJMoa1206524 (2012). 
9 Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 
536, 285-291, doi:10.1038/nature19057 (2016). 
10 Short, P. J. et al. De novo mutations in regulatory elements in neurodevelopmental 
disorders. Nature 555, 611-616, doi:10.1038/nature25983 (2018). 
11 Lupski, J. R. Digenic inheritance and Mendelian disease. Nat Genet 44, 1291-1292, 
doi:10.1038/ng.2479 (2012). 
12 Zhang, F. & Lupski, J. R. Non-coding genetic variants in human disease. Hum Mol 
Genet 24, R102-110, doi:10.1093/hmg/ddv259 (2015). 
13 Posey, J. E. et al. Resolution of Disease Phenotypes Resulting from Multilocus 
Genomic Variation. N Engl J Med 376, 21-31, doi:10.1056/NEJMoa1516767 (2017). 
14 Richards, S. et al. Standards and guidelines for the interpretation of sequence 
variants: a joint consensus recommendation of the American College of Medical 
Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17, 
405-424, doi:10.1038/gim.2015.30 (2015). 
 
 
1-14  
 
